NITRO BIOSCIENCES INC.

Biotech · Private

Engineered vaccine platform using chemically modified antigens to direct immune responses toward conserved pathogen regions

Grants
$304K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: A platform to overcome immunodominance in vaccine development$304,438
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1137Synata Bio, Inc.—$52M
1138SYNSORYBIO, INC.——
1139ELEX BIOTECH, LLC——
1140NITRO BIOSCIENCES INC.——
1141PROTON BIO, INC.——
1142REZIGENE, LLC——
1143Optivia Biotechnology Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Biosynthesis Of Para-nitro-l-phenylalanineapplication
  • Biosynthesis Of Para-nitro-l-phenylalanineapplication
  • Biosynthesis Of Para-nitro-l-phenylalanineapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.